<DOC>
	<DOCNO>NCT00928148</DOCNO>
	<brief_summary>This phase 2 , randomize , multi-center , double-blind , 3-period 3-treatment crossover study design evaluate safety duration efficacy SPD465 ( 50 75 mg ) compare placebo immediate release amphetamine salt formulation ( 25 mg ) adult ADHD . The controlled environment use study analog classroom set adapt 16-hour adult day .</brief_summary>
	<brief_title>The Safety Efficacy SPD465 Adults With Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<criteria>Adult men nonpregnant woman age 18 55 Confirmed diagnosis ADHD define Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) Baseline ADHD score least 24 Weight less 100 pound great 250 pound Psychiatric diagnosis severe comorbid Axis II Axis I disorder Pregnancy breastfeed History seizure Positive urine drug screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>